Blasco P A, Stansbury J C
Gillette Children's Hospital, St Paul, Minn, USA.
Arch Pediatr Adolesc Med. 1996 Sep;150(9):932-5. doi: 10.1001/archpedi.1996.02170340046009.
To describe the use of glycopyrrolate in the control of drooling in children and young adults with cerebral palsy and related neurodevelopmental disabilities.
Prospective, open-label study of drug dosage parameters, response to therapy, and side effects. Follow-up ranged from 8 months to 4 years.
Outpatient clinic of a rehabilitation hospital that is a regional referral center for children with disabilities.
Forty children and young adults with motor and/or cognitive disabilities who were experiencing drooling to a severe degree.
Treatment with oral glycopyrrolate.
Change in the quantity of drooling and side effects associated with treatment.
Thirty-six patients (90%) had reduced drooling in response to medication; 2 (5%) could not be assessed and 2 (5%) received no benefit. Side effects resulted in discontinuation of treatment in 11 (28%). Overall, 26 (65%) continued to receive drug therapy because of the perceived benefit. The final effective dose ranged widely from 0.01 to 0.82 mg/kg per day.
Glycopyrrolate therapy safely and effectively decreased but rarely abolished drooling in patients with cerebral palsy and related neurodevelopmental disabilities. The dose range was surprisingly broad. Side effects, although generally minor and predictable, often led to discontinuation of drug therapy.
描述格隆溴铵在控制患有脑瘫及相关神经发育障碍的儿童和青年流涎方面的应用。
关于药物剂量参数、治疗反应及副作用的前瞻性开放标签研究。随访时间为8个月至4年。
一家康复医院的门诊，该医院是残疾儿童的区域转诊中心。
40名患有运动和/或认知障碍且流涎严重的儿童和青年。
口服格隆溴铵治疗。
流涎量的变化及与治疗相关的副作用。
36名患者（90%）用药后流涎减少；2名（5%）无法评估，2名（5%）未获益处。副作用导致11名患者（28%）停药。总体而言，26名患者（65%）因感觉有益而继续接受药物治疗。最终有效剂量范围很广，从每天0.01至0.82毫克/千克。
格隆溴铵治疗能安全有效地减少患有脑瘫及相关神经发育障碍患者的流涎，但很少能消除流涎。剂量范围出人意料地宽。副作用虽通常轻微且可预测，但常导致停药。
